Cell & Gene Therapy Manufacturing Services Market Report 2025

The cell & gene therapy manufacturing services market size has grown rapidly in recent years. It will grow from $8.15 billion in 2024 to $9.46 billion in 2025 at a compound annual growth rate (CAGR) of 16.1%. The growth in the historic period can be attributed to increased R&D investments, regulatory support and frameworks, growing pipeline of cell & gene therapies, industry collaborations and partnerships, increasing global demand for personalized medicine.

The cell & gene therapy manufacturing services market size is expected to see rapid growth in the next few years. It will grow to $17.97 billion in 2029 at a compound annual growth rate (CAGR) of 17.4%. The growth in the forecast period can be attributed to market maturation and commercialization, global expansion of biopharmaceutical manufacturing, increased outsourcing by pharma companies, advancements in automation and robotics, emergence of new therapeutic modalities. Major trends in the forecast period include rising demand for energy efficiency, advanced materials and technologies, compact and modular designs, electrification of transportation, focus on safety and reliability.

The cell and gene therapy manufacturing services market is anticipated to experience growth due to the increasing prevalence of diseases such as cancer. Cancer's rapid and uncontrolled cell growth has led to a surge in demand for more effective treatments, spurring the development of cell and gene therapies. For example, in January 2023, the American Cancer Society reported a 3.16% increase in cancer cases from 2021 to 2023, highlighting the escalating need for innovative therapies to address this trend.

The market for cell and gene therapy manufacturing services is expected to expand further owing to the rising adoption of personalized medicine. This approach tailors medical treatments to individual patient characteristics, significantly enhancing the efficacy of cell and gene therapies. Notably, in January 2023, the FDA's Center for Drug Evaluation and Research approved 37 new molecular entities in 2022, with 12 of them classified as personalized medicines by the Personalized Medicine Coalition (PMC), signifying the growing prominence of personalized treatments.

Technological advancements are driving trends in the cell and gene therapy manufacturing services market. Companies are embracing innovative technologies to maintain their market positions. For instance, in October 2022, Charles River Laboratories International Inc. introduced the navigation Vector Platform, simplifying GMP Adeno-Associated Virus (AAV) vector manufacturing. This platform drastically reduces the time required for viral vector gene therapy researchers compared to conventional workflows, enhancing efficiency and scalability.

Collaborations and partnerships among key players are reshaping the cell and gene therapy manufacturing services market, fostering innovation and accelerating product development. An instance is the collaboration between Allogene Therapeutics Inc. and Antion Biosciences SA to advance multiplex gene silencing for developing next-generation allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer.

In June 2024, Genezen, a gene and cell therapy company based in the United States, acquired UniQure for an undisclosed sum. This acquisition is intended to bolster Genezen’s capabilities in gene therapy production, broaden its range of services, and utilize UniQure’s expertise to address the increasing demand for innovative gene therapies in the market. UniQure is a biotechnology company located in the Netherlands that focuses on gene therapies for severe diseases.

Major companies operating in the cell & gene therapy manufacturing services market include Thermo Fisher Scientific Inc., Merck KGaA, Charles River Laboratories International Inc., Lonza Group AG, Catalent Inc., WuXi AppTec, Takara Bio Inc., Nikon Corporation, Fujifilm Holdings Corporation, F. Hoffmann-La Roche Ltd, Oxford Biomedica plc, CGT Catapult, bluebird bio Inc., Boehringer Ingelheim International GmbH, Innovative Cellular Therapeutics Co. Ltd., Samsung Biologics Co. Ltd., Novartis International AG, Pfizer Inc., Brammer Bio, AGC Biologics, Cognate BioServices Inc., Paragon Bioservices Inc., Merck KGaA operating as MilliporeSigma, Sarepta Therapeutics Inc., Spark Therapeutics Inc., Orchard Therapeutics plc, Precision BioSciences Inc., PCT a Hitachi Group Company, Aldevron LLC, BioNTech SE.

North America was the largest region in the cell and gene therapy manufacturing services market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global cell & gene therapy manufacturing services market report forecast period. The regions covered in the cell & gene therapy manufacturing services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell & gene therapy manufacturing services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cell and gene therapy manufacturing services encompass processes dedicated to manufacturing and ensuring the quality of gene and cell therapy products. These services play a pivotal role in developing treatments for degenerative conditions, tissue injuries, and genetic abnormalities. They involve adhering to good manufacturing practices, utilizing ancillary reagents, conducting flow cytometry and immunoassays, and offering gene engineering services.

The primary types of these manufacturing services include gene therapy and cell therapy. Gene therapy involves addressing underlying genetic issues to treat or prevent diseases. These services cater to both commercial manufacturing and clinical applications, targeting diverse medical indications such as central nervous system disorders, ophthalmology diseases, cardiovascular diseases, infectious diseases, orthopedic diseases, and oncology diseases. These specialized services are utilized by academic and research institutes, pharmaceutical and biotechnology companies, and other relevant entities involved in the development and production of cell and gene therapies aimed at addressing various medical conditions.

The cell and gene therapy manufacturing services market research report is one of a series of new reports that provides cell and gene therapy manufacturing services optical components market statistics, including cell and gene therapy manufacturing services optical components industry global market size, regional shares, competitors with a cell and gene therapy manufacturing services optical components market share, detailed cell and gene therapy manufacturing services optical components market segments, market trends and opportunities, and any further data you may need to thrive in the cell and gene therapy manufacturing services optical components industry. This cell and gene therapy manufacturing services optical components market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cell and gene therapy manufacturing services market includes revenues earned by cell and gene therapy manufacturing and related services which include analytical and process development, current good manufacturing practice cell therapy manufacturing services of autologous and allogeneic t-cells, natural killer cells, dendritic cells, mesenchymal stem cells, hematopoietic stem cells, and more. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.